Bulletin of the World Health Organization

Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya

Angela Oloo Akumu, Mike English, J Anthony G Scott, Ulla K Griffiths

Volume 85, Number 7, July 2007, 511-518

Table 4. Incremental cost-effectiveness of Hib vaccine in Kenya: base case scenario (2004)

Vaccine and injection equipment Treatment costs(US$) Net costs(US$) Hib cases Hibdeaths Disability adjusted life years (DALYs) Costs (US$) per case averted(95% CI) Costs (US$) per death averted(95% CI) Costs (US$) per DALY averted(95% CI)
Undiscounted results:
No Hib vaccination 7 211 835 984 958 8 196 793 27 347 6 112 401 568
Hib vaccination 14 428 334 113 419 14 541 753 3 149 704 46 243
Increment 7 216 499 –871 539 6 344 960 24 198 5 408 355 325 262(175–455) 1 173(797–1982) 18(12–30)
Discounted results (3%):
No Hib vaccination 7 211 835 967 758 6 244 077 26 870 6 005 191 489
Hib vaccination 14 428 334 111 439 14 316 895 3 094 691 22 052
Increment 7 216 499 –56 319 6 360 180 23 775 5 314 169 438 268(178–464) 1 197(814–2021) 38(26–63)

CI, confidence interval; Hib, Haemophilus influenzae type b.

[an error occurred while processing this directive]